Intravesical bacillus Calmette-Guérin is the current first-line treatment for high-grade nonmuscle-invasive bladder cancer; however, a substantial proportion of patients are unresponsive to bacillus Calmette-Guérin treatment. While cystectomy...
Herein, we examined the use of BCG vaccine treatment in patients with NMIBC and the risk of death and dementia. To our knowledge, we present the largest-to-date population health study of intravesical BCG vaccine for bladder cancer and ADRD, using electronic health records from patients ...
Another concept is that of therapeutic immunisation which seeks to shorten or adapt treatment regimens with adjuvant vaccines which may be particularly valuable for drug-resistant TB (Fig. 2). Download: Download high-res image (323KB) Download: Download full-size image Fig. 2. Novel TB vaccine...
37,38 The immunity of prevention and treatment are different; BCG might function as an effective preventive measure but not as a treatment for lung cancer. The BCG vaccine was not associated with a decreased rate of bladder cancer in this study (HR, 1.34; 95% CI, 0.22-8.03). Strengths ...
that immunotherapy for bladder cancer has been successfully used for almost 40 years. BCG was first introduced into clinical use in urology in 1976 and remains the most effective form of intravesical treatment for non-muscle-invasive bladder cancer (NMIBC). Despite this successful history, BCG thera...
PDE cancer Treatment modelBCG immunotherapy has shown significant success for bladder cancer treatment, but due to the complexity of the interaction between immunity and cancer, clinical outcomes vary significantly between patients. A possible approach to overcome this difficulty may be to develop new ...
n a phase 2 study of patients with BCG-unresponsive non–muscle invasive bladder cancer, treatment with recombinant pox-viral vector vaccine Panvac plus bacillus Calmette-Guérin did not significantly improve clinical outcomes.
Patients without recurrence then underwent maintenance therapy with monthly instillations for two years. Treatment success was defined as no bladder cancer recurrence and no cystectomy. Survival analysis was performed using the Kaplan Meier method. Results: 30 patients were treated with a median follow-...
Experts will recognize, however, that immunotherapy for bladder cancer has been successfully used for almost 40 years. BCG was first introduced into clinical use in urology in 1976 and remains the most effective form of intravesical treatment for non-muscle-invasive bladder cancer (NMIBC). Despite ...
Advanced Bladder Cancer For patients with advanced disease, platinum-basedcombination chemotherapyhas been the first-line treatment for decades, with cisplatin-based treatments yielding a better overall survival than carboplatin-based combinations (12-15 months vs. 9 months).62,63However most patients pr...